CN116751818A - 一种重组流感病毒载体治疗性高血压疫苗的制备方法 - Google Patents
一种重组流感病毒载体治疗性高血压疫苗的制备方法 Download PDFInfo
- Publication number
- CN116751818A CN116751818A CN202311001106.9A CN202311001106A CN116751818A CN 116751818 A CN116751818 A CN 116751818A CN 202311001106 A CN202311001106 A CN 202311001106A CN 116751818 A CN116751818 A CN 116751818A
- Authority
- CN
- China
- Prior art keywords
- gene
- vaccine
- influenza virus
- recombinant
- influenza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010020772 Hypertension Diseases 0.000 title claims abstract description 56
- 229960005486 vaccine Drugs 0.000 title claims abstract description 48
- 241000712461 unidentified influenza virus Species 0.000 title claims abstract description 47
- 239000013598 vector Substances 0.000 title claims abstract description 32
- 230000001225 therapeutic effect Effects 0.000 title claims abstract description 29
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 38
- 238000000034 method Methods 0.000 claims abstract description 21
- 241000712431 Influenza A virus Species 0.000 claims abstract description 15
- 239000002773 nucleotide Substances 0.000 claims abstract description 12
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 12
- 101800000733 Angiotensin-2 Proteins 0.000 claims abstract description 10
- 102000004338 Transferrin Human genes 0.000 claims abstract description 10
- 108090000901 Transferrin Proteins 0.000 claims abstract description 10
- 229950006323 angiotensin ii Drugs 0.000 claims abstract description 10
- 230000002238 attenuated effect Effects 0.000 claims abstract description 10
- 239000012581 transferrin Substances 0.000 claims abstract description 10
- 230000006978 adaptation Effects 0.000 claims abstract description 5
- 102000005862 Angiotensin II Human genes 0.000 claims abstract 3
- 230000002457 bidirectional effect Effects 0.000 claims description 33
- 239000013613 expression plasmid Substances 0.000 claims description 33
- 150000001413 amino acids Chemical group 0.000 claims description 24
- 210000004027 cell Anatomy 0.000 claims description 23
- 101000766306 Homo sapiens Serotransferrin Proteins 0.000 claims description 22
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 claims description 22
- 239000012634 fragment Substances 0.000 claims description 14
- 238000002649 immunization Methods 0.000 claims description 12
- 230000003053 immunization Effects 0.000 claims description 12
- 108700029658 influenza virus NS Proteins 0.000 claims description 9
- 238000002347 injection Methods 0.000 claims description 8
- 239000007924 injection Substances 0.000 claims description 8
- 101150076514 NS gene Proteins 0.000 claims description 7
- 101150033828 NS1 gene Proteins 0.000 claims description 7
- 238000012258 culturing Methods 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 230000036541 health Effects 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 230000008520 organization Effects 0.000 claims description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 5
- 101150080862 NA gene Proteins 0.000 claims description 4
- 101150118742 NP gene Proteins 0.000 claims description 4
- 101150105115 PA gene Proteins 0.000 claims description 4
- 101150103639 PB1 gene Proteins 0.000 claims description 4
- 101150030427 PB2 gene Proteins 0.000 claims description 4
- 230000004048 modification Effects 0.000 claims description 4
- 238000012986 modification Methods 0.000 claims description 4
- 101150039660 HA gene Proteins 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- 238000005571 anion exchange chromatography Methods 0.000 claims description 3
- 238000004587 chromatography analysis Methods 0.000 claims description 3
- 238000000432 density-gradient centrifugation Methods 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 238000000746 purification Methods 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- 238000000108 ultra-filtration Methods 0.000 claims description 3
- 241000590002 Helicobacter pylori Species 0.000 claims description 2
- 101100221606 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) COS7 gene Proteins 0.000 claims description 2
- 229940037467 helicobacter pylori Drugs 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract description 14
- 230000002441 reversible effect Effects 0.000 abstract description 12
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 229960003971 influenza vaccine Drugs 0.000 abstract description 6
- 102000036639 antigens Human genes 0.000 abstract description 4
- 108091007433 antigens Proteins 0.000 abstract description 4
- 238000003776 cleavage reaction Methods 0.000 abstract description 4
- 230000003042 antagnostic effect Effects 0.000 abstract description 3
- 239000000427 antigen Substances 0.000 abstract description 3
- 230000030741 antigen processing and presentation Effects 0.000 abstract description 2
- 239000012645 endogenous antigen Substances 0.000 abstract description 2
- 230000007017 scission Effects 0.000 abstract description 2
- 101500024730 Homo sapiens Angiotensin-2 Proteins 0.000 abstract 1
- 108700032552 influenza virus INS1 Proteins 0.000 abstract 1
- 239000007788 liquid Substances 0.000 description 27
- 241000700605 Viruses Species 0.000 description 22
- 101710128560 Initiator protein NS1 Proteins 0.000 description 18
- 101710144127 Non-structural protein 1 Proteins 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 238000005406 washing Methods 0.000 description 18
- 101710158312 DNA-binding protein HU-beta Proteins 0.000 description 17
- 230000036772 blood pressure Effects 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 238000005516 engineering process Methods 0.000 description 9
- 239000002105 nanoparticle Substances 0.000 description 9
- 102000011931 Nucleoproteins Human genes 0.000 description 8
- 108010061100 Nucleoproteins Proteins 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 238000001890 transfection Methods 0.000 description 8
- 102400000345 Angiotensin-2 Human genes 0.000 description 7
- 210000003837 chick embryo Anatomy 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 201000001320 Atherosclerosis Diseases 0.000 description 6
- 102100037516 Protein polybromo-1 Human genes 0.000 description 6
- 101710085035 RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 238000010586 diagram Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 101710102873 Polymerase basic protein 2 Proteins 0.000 description 5
- 230000003276 anti-hypertensive effect Effects 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 101710154606 Hemagglutinin Proteins 0.000 description 4
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 4
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 4
- 101710176177 Protein A56 Proteins 0.000 description 4
- 230000002745 absorbent Effects 0.000 description 4
- 239000002250 absorbent Substances 0.000 description 4
- 230000035487 diastolic blood pressure Effects 0.000 description 4
- 239000000539 dimer Substances 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000185 hemagglutinin Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012544 monitoring process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 230000010076 replication Effects 0.000 description 4
- 238000007789 sealing Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000010009 beating Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000003306 harvesting Methods 0.000 description 3
- 230000001631 hypertensive effect Effects 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001338 self-assembly Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 230000035488 systolic blood pressure Effects 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- 102000008873 Angiotensin II receptor Human genes 0.000 description 2
- 108050000824 Angiotensin II receptor Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
- 108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241000713297 Influenza C virus Species 0.000 description 2
- 229940124873 Influenza virus vaccine Drugs 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108010006232 Neuraminidase Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- 102000002689 Toll-like receptor Human genes 0.000 description 2
- 108020000411 Toll-like receptor Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000004186 co-expression Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 238000003795 desorption Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 210000003000 inclusion body Anatomy 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 102000007863 pattern recognition receptors Human genes 0.000 description 2
- 108010089193 pattern recognition receptors Proteins 0.000 description 2
- 230000001603 reducing effect Effects 0.000 description 2
- 239000012898 sample dilution Substances 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 230000002269 spontaneous effect Effects 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229940021747 therapeutic vaccine Drugs 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- 101150033839 4 gene Proteins 0.000 description 1
- PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 description 1
- PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 206010049993 Cardiac death Diseases 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 102000001187 Collagen Type III Human genes 0.000 description 1
- 108010069502 Collagen Type III Proteins 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 206010011906 Death Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000002979 Influenza in Birds Diseases 0.000 description 1
- 102000002227 Interferon Type I Human genes 0.000 description 1
- 108010014726 Interferon Type I Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108060004795 Methyltransferase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 241000712464 Orthomyxoviridae Species 0.000 description 1
- 102100025386 Oxidized low-density lipoprotein receptor 1 Human genes 0.000 description 1
- 101710199789 Oxidized low-density lipoprotein receptor 1 Proteins 0.000 description 1
- -1 PA) Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 206010049190 Red blood cell agglutination Diseases 0.000 description 1
- 108090000783 Renin Proteins 0.000 description 1
- 102100028255 Renin Human genes 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000010913 Type 1 Angiotensin Receptor Human genes 0.000 description 1
- 108010062481 Type 1 Angiotensin Receptor Proteins 0.000 description 1
- 102000025309 Type 2 Angiotensin Receptor Human genes 0.000 description 1
- 108010062475 Type 2 Angiotensin Receptor Proteins 0.000 description 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 description 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 description 1
- 206010047139 Vasoconstriction Diseases 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 230000004872 arterial blood pressure Effects 0.000 description 1
- 206010064097 avian influenza Diseases 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 244000309457 enveloped RNA virus Species 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000013095 identification testing Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000951 immunodiffusion Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 108700015453 influenza virus PB2 Proteins 0.000 description 1
- 108010064513 influenza virus polymerase basic protein 1 Proteins 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000813 peptide hormone Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000008664 renal activity Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000011699 spontaneously hypertensive rat Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 1
- 230000025033 vasoconstriction Effects 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/79—Transferrins, e.g. lactoferrins, ovotransferrins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/14—Angiotensins: Related peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
- C12N2760/16152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Mycology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明公开了一种重组流感病毒载体治疗性高血压疫苗的制备方法。属于疫苗生物制品技术领域。该方法是将2A酶切位点后9个人血管紧张素Ⅱ基因与转铁蛋白进行串联后取代流感病毒NS1的280~340bp的核苷酸序列。同时利用甲型流感病毒冷适应减毒株和流感疫苗候选株的基因片段,完成反向遗传学的流感病毒拯救。本发明的主要用途是皮内注射高血压患者,使得血管紧张素Ⅱ蛋白在机体内表达,完成内源性抗原提呈,刺激机体产生相应抗体,从而拮抗高血压患者体内高水平的血管紧张素Ⅱ,达到治疗高血压的目的。与此同时由于重组流感病毒载体表面携带流感疫苗株的表面抗原,可同时达到流感疫苗使用的目的。
Description
技术领域
本发明涉及疫苗生物制品技术领域,更具体的说是涉及一种重组流感病毒载体治疗性高血压疫苗的制备方法。
背景技术
流感病毒属于正粘病毒科,单链分节段的负链RNA基因。甲型流感病毒可感染多种哺乳动物(例如猪和马)和禽类,而丙型流感病毒的感染很大程度上仅限于人类。引起人类疾病的只有甲型和乙型流感病毒。目前确定的大多数甲型流感病毒保留了10种NA和17种HA亚型。流感病毒属于有囊膜的RNA病毒,基因组由八个分节段的线性基因片段构成(丙型流感病毒只有七个基因片段),八个基因片段编码十个蛋白,分别为:RNA依赖性RNA聚合酶(PB2,PB1,PA),形成核衣壳的核蛋白(NP),基质膜蛋白(M),两个表面膜蛋白(血凝素HA和神经氨酸酶NA),非结构蛋白(NS1和NS2)和核出运蛋白(NEP)。
多数人和禽类易感的甲型流感病毒的NS基因,其长度为890个核苷酸,有一个开放读码框编码NS1蛋白,其长度一般为202~237个氨基酸。这种差异是由不同毒株所造成的,有的病毒株其NS1蛋白仅含有124个氨基酸,并且该毒株在组织培养中能形成空斑,同时对火鸡具有高感染性,这表明NS1的C末端超过一半的氨基酸对它的功能是可有可无的。有些病毒株在感染后期,NS1能够形成电子致密的半结晶状的包涵体,这种包涵体在流感病毒感染中刺激机体天然免疫应答具有一定的作用。
NS2的mRNA含有473个核苷酸的一个间断区,它的5’末端前56个核苷酸与NS1的mRNA的5’末端是相同的,从529位又开始继续。
流感病毒基因组可以被基因改造,包括缺失和插入的变异,因此人们尝试通过缺失的位置改造流感病毒,如神经氨酸酶基因(NA)和非结构蛋白1(NS1)等。流感病毒反向遗传学技术的进步和流感病毒载体技术的发展为流感病毒载体的广泛应用带来了机会。
高血压是一种最常见的却又危害严重的慢性疾病,是全球疾病负担最严重的疾病。全球估计有12.8亿30~79岁成年人患有高血压,其中约三分之二生活在低收入和中等收入国家。在我国高血压成为致病致残的第一病因,每年高血压的医疗费用高达318.9亿元,直接经济损失超过2103亿元。根据最新调查数据显示,我国高血压患者已突破3.3亿,中青年高血压(18~64岁)患者约占总体高血压人群的78%。
高血压病及其并发症的危害性往往十分严重,长期不加控制的高血压会导致心血管系统的病变,如动脉粥样硬化、冠心病、心力衰竭、心律失常、心肌梗死等。同时,高血压还会对肾脏、视网膜、大脑等器官造成损害。高血压还是中风和脑卒中的高危因素之一。据统计,高血压是导致全球死亡率居高不下的心血管疾病之一,成为全球范围内的健康问题。高血压是动脉粥样硬化的一种重要危险因素,进而引发心肌梗死,机体左室重构,引发心室扩张,导致充血性心力衰竭,并与终末期心脏病死亡密切相关。
大多数患者发生高血压,需要长期服用药物,超过30%的患者需要两种药物联合治疗。由于患者长期服用药物,患者依从性差,并会产生不良的副作用,降低生命质量。高血压疫苗是治疗高血压的新型药物,主要是通过疫苗,诱导和增强抗体特性的免疫反应,可以控制血压、预防并发症,成为治疗高血压和动脉粥样硬化(AS)的新型有效手段,并且有助于改善AS疾病症状。
Angiotensin II human(Angiotensin II)是一种血管收缩剂,是肾素/血管紧张素系统的主要生物活性肽。Angiotensin II human在调节人类血压中起着核心作用,主要通过血管紧张素II与G蛋白偶联受体(GPCRs)、血管紧张素II 1型受体(AT1R)和血管紧张素II 2型受体(AT2R)之间的相互作用来介导。Angiotensin II Human刺激交感神经兴奋,增加醛固酮生物合成和肾脏活动。Angiotensin II Human诱导血管平滑肌细胞生长,增加成纤维细胞中I型和III型胶原的合成,导致血管壁和心肌增厚,并导致纤维化。AngiotensinII Human也诱导细胞凋亡(apoptosis)。Angiotensin II Human通过LOX-1依赖的氧化还原敏感途径诱导内皮细胞毛细血管生成,并且与AS的发生和发展密切相关。
治疗性高血压疫苗的工作机制主要立足于肾素-血管紧张素-醛固醇系统(therenin-angiotensin-aldosteron system, RAAS),由于它的过度激活是高血压最重要的发病机制,血管紧张素Ⅱ(AngⅡ)与小血管肌肉细胞表面的1型血管紧张素受体(AT1R)结合,引起血管收缩,它还能促进肾脏对钠的再吸收,血管收缩和钠的再吸收都会导致血压升高(图1)。因此如果机体产生AngⅡ特异性受体竞争性结合AngⅡ,就能有效降低血压。但是由于AngⅡ分子量小,它含有八个氨基酸的激素肽,结构简单,免疫原性弱,半衰期短等原因使AngⅡ相关疫苗的研究十分困难。
2007年瑞士Cytos生物技术公司研发的AngⅡ降压疫苗(CYT006-AngQβ)在Ⅱa期临床试验中显示出良好降压效果和安全性,曾经被认为是极有希望的降压疫苗,但是后续研究发现该疫苗的抗体亲和力及反馈性的Ang II升高等问题限制了其降压作用。
治疗性高血压疫苗一直是国内研究的空白领域,目前研究较深入的是华中科技大学的廖玉华教授发明的ATRQβ-001疫苗,具有良好的降压效果,但是需要每个月注射一次,将来患者依从性可能不高,或出现多次免疫注射后的免疫耐受。同时该疫苗是基于噬菌体表达技术的疫苗制备,噬菌体相关疫苗目前尚无任何一款产品上市应用到人体,所以其安全性需要大量研究支持。
综上,如何提供一种治疗效果好、注射频次少、安全性高的高血压治疗性疫苗是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了一种重组流感病毒载体治疗性高血压疫苗的制备方法。
为了实现上述目的,本发明采用如下技术方案:
一种重组流感病毒载体治疗性高血压疫苗的制备方法,包括如下步骤:
(1)对流感病毒NS基因进行目的性改造:
将原NS1基因的237个氨基酸序列截短为前113个氨基酸,在其后面依次插入2A肽氨基酸序列,增加9个重复的血管紧张素Ⅱ氨基酸序列,增加转铁蛋白氨基酸序列,然后连接上NS2氨基酸序列,得改造后流感病毒NS基因片段;
(2)将所述改造后流感病毒NS基因片段与双向表达质粒连接,构建重组双向表达质粒,命名为re-NS;
(3)将甲型流感病毒冷适应减毒株作为母本株,分别将其基因片段PB2基因、PB1基因、PA基因、M基因、NP基因与双向表达质粒连接,构建重组双向表达质粒,分别命名为:AA-PB2、AA-PB1、AA-PA、AA-M、AA-NP;
(4)将世界卫生组织在北半球推荐使用的甲型流感病毒毒株的HA基因和NA基因分别与双向表达质粒连接,构建重组双向表达质粒,分别命名为re-HA、re-NA;
(5)在大肠杆菌中进行重组双向表达质粒的扩增,然后提取质粒并进行纯化,之后通过流感病毒反向遗传学技术,将构建的8个重组双向表达质粒共转染哺乳动物细胞,培养收毒即可(利用宿主细胞内的蛋白酶完成了流感病毒基因组的翻译表达和逆转录,从而包装成具有活性的病毒颗粒,完成病毒拯救,并具备上述基因片段的遗传稳定性)。
PB2基因的核苷酸序列如SEQ ID NO.8所示。
agcaaaagcaggtcaattatattcaatatggaaagaataaaagaactacggaatctgatgtcgcagtctcgcactcgcgagatactaacaaaaaccacagtggaccatatggccataattaagaagtacacatcagggagacaggaaaagaacccgtcacttaggatgaaatggatgatggcaatgaaatatccgattacagctgacaagaggataacagaaatgattcctgagagaaatgagcaagggcaaactctatggagtaaaatgagtgatgccggatcggatcgagtgatggtatcacctctggctgtgacatggtggaatagaaatggaccaatgacaagtacggttcattatccaaaaatctacaaaacttattttgagaaagtcgaaaggttaaaacatggaacctttggccctgtccattttagaaaccaagtcaaaatacgccgaagagttgacataaatcctggtcatgcagacctcagtgccaaggaggcacaggatgtaatcatggaagttgttttccctaacgaagtgggggccaggatactaacgtcggaatcgcaattaacaataaccaaagagaaaaaagaagaactccaggattgcaaaatttctcctttgatggttgcgtacatgttagagagagaacttgtccgaaaaacgagatttctcccagttgctggtggaacaagcagtgtgtacattgaagtgttgcacttgactcaaggaacatgctgggaacagatgtacactccaggtggagaagtgaggaatgatgatgttgatcaaagtctaattattgcagccaggaacatagtgagaagagcagcagtatcagcagatccactagcatctttattggagatgtgccacagcacacagattggcgggacaaggatggtggacattcttaggcagaacccaacggaagagcaagctgtggatatatgcaaggctgcaatgggactgagaatcagctcatccttcagttttggcgggttcacatttaagagaacaagcggatcatcagtcaagagagaggaagaagtgcttacgggcaatcttcaaacattgaaaataagggtgcatgagggatacgaggagttcacaatggttgggaaaagggcaacagctatactcagaaaagcaaccaggagattgattcagctgatagtgagtggaagagacgaacagtcgatagccgaagcaataattgtggccatggtattttcacaagaagattgtatgataaaagcagttagaggtgatctgaatttcgttaatagggcaaatcagcgattgaatcccatgcatcaacttttaagacattttcagaaggatgcgaaagtgctttttcaaaattggggaattgaacatatcgacaatgtgatgggaatgattggggtattaccagacatgactccaagcacagagatgtcaatgagagggttaagagtcagcaaaatgggcgtagatgaatactccagcgcggagagagtagtggtgagcattgaccggtttttgagagttcgagaccaacgaggaaatgtactattatctcctgaggaggtcagtgaaacacagggaacagagaaactgacaataacttactcatcgtcaatgatgtgggagattaatggccctgagtcagtgttggtcaatacctatcagtggatcatcagaaactgggaaactgttaaaattcagtggtctcagaatcctacaatgctatacaataaaatggaatttgagccatttcagtctttagttcctaaggccattagaggccaatacagtgggtttgttaggactctattccaacaaatgagggatgtacttgggacatttgataccacccagataataaaacttcttccctttgcagccgccccaccaaagcaaagtagaatgcagttctcttcattgactgtgaatgtgaggggatcaggaatgagaatacttgtaaggggcaattctcctgtattcaactacaacaagaccactaagagactaacaattctcggaaaggatgctggcactttaactgaagacccagatgaaggcacatctggagtggagtccgctgttctgagaggattcctcattctgggcaaagaagataggagatatggaccagcattaagcatcaatgaactgagtaaccttgcgaaaggagaaaaggctaatgtactaattgggcaaggagacgtggtgttggtaatgaaacgaaaacgggactctagcatacttactgacagccagacagcgaccaaaagaattcggatggccatcaattaatgtcgaatagtttaaaaacgaccttgtttctact,SEQ IDNO.8。
PB1基因的核苷酸序列如SEQ ID NO.9所示。
agcaaaagcaggcaaaccatttgaatggatgtcaatccgaccttacttttcttgaaagttccagcgcaaaatgccataagtactacattcccttatactggagatcctccatacagccatggaacaggaacaggatacaccatggacacagtcaacagaacacatcaatattcagaaaaggggaagtggacaacaaacacggaaactggagcgccccaacttaacccaattgatggaccactacctgaggacaatgaaccaagtggatatgcacaaacagactgcgtcctggaagcaatggctttccttgaagaatcccacccaggaatctttgaaaactcgtgtcttgaaacgatggaggttattcaacaaacaagagtggacaaactgacccaaggtcgtcagacctatgattggacattgaacagaaatcagccggctgcaactgcgctagccaacactatagaggtcttcagatcgaatggtctgacagctaatgaatcgggaaggctaatagatttcctcaaggatgtgatagaatcaatggataaagaggagatggaaataacaacacacttccaaagaaaaagaagagtaagagacaacatgaccaagaaaatggtcacacaacgaacaataggaaagaagaagcaaagattgaacaagagaatctatctaataagagcactgacattgaacacaatgactaaagatgcagagagaggtaaattaaagagaagagcaattgcaacacccggtatgcagatcagagggttcgtgtactttgtcgaaacactagcgagaagtatttgtgagaatcttgaacagtctgggcttccggttggaggtaatgaaaagaaggctaaactggcaaatgttgtgagaaaaatgatgactaattcacaagacacagagctctctttcacaattactggagacaataccaaatggaatgagaatcaaaatcctcggatgttcctggcgatgataacatacatcacaagaaatcaacctgaatggtttagaaacgtcctgagcatcgcacctataatgttctcaaataaaatggcaagactagggaaaggatacatgttcaaaagcaagagcatgaagctccgaacacaaataccagcagaaatgctaacaagtattgacctgaaatactttaatgaatcaacaagaaagaaaatcgagaaaataaggcctctcctaatagatggcacagtctcattgagtcctggaatgatgatgggcatgttcaacatgctaagtacagtcttaggagtctcaatcctgaatcttggacaaaagaagtacaccaaaacaacatactggtgggacggactccaatcctctgatgacttcgccctcatagtgaatgcaccaaatcatgagggaatacaagcaggagtggatagattctacagaacctgcaagctagtcggaatcaatatgagcaaaaagaagtcctacacaaataggacagggacatttgaattcacaagctttttctatcgctatggatttgtagccaattttagcatggagctgcccagctttggagtgtctggaattaatgaatcggatgatatgagcattggggtaacagtgataaagaacaacatgataaacaatgaccttgggccagcaacagcccaaatggctcttcaactattcatcaaagactacagatatacgtaccggtgccacagaggagacacacaaattcagacaaggagatcattcgagctaaagaagctgtgggagcaaacccgctcaaaggcaggacttttgatttctgatggaggaccaaacttatacaatatccggaatctccacattccagaagtctgcttgaagtgggagctaatggatgaagactatcaggggaggctttgtaatcccctgaatccatttgtcagtcataaggagattgagtctgtaaacaatgctgtggtaatgccagctcacggtccagccaagagcatggaatatgatgctgttgctactacacactcctggatccctaagaggaaccgctccattctcaacacaagccaaaggggaattcttgaggatcaacagatgtatcagaagtgttgcaatctattcgagaaattcttccctagcagttcgtacaggagaccagttggaatttccagcatggtggaggccatggtgtctagggcccggattgatgcacggattgacttcgagtctggacggattaagaaagaggagttcgctgagatcatgaagatctgttccaccattgaagagctcagacggcaaaaatagtgaatttagcttgtccttcatgaaaaaatgccttgtttctact,SEQ IDNO.9。
PA基因的核苷酸序列如SEQ ID NO.10所示。
agcaaaagcaggtactgatccgaaatggaagaatttgtgcgacaatgcttcaatccgatgattgtcgagcttgctgaaaaagcaatgaaagagtatggagaggatcggaaaatcgaaacaaacaaatttgcagcaatatgcactcacttggaagtatgcttcatgtattcagattttcatttcatcaatgagcaaggcgagtcaataatagtagagcttgatgatccaaatgcacttttgaagcacagatttgaaataatagagggaagagatcgcacaatggcctggacagtagtaaacagtatttgcaacactacaggagctgagaaaccgaagtttctgccagatttgtatgattacaaggagaatagattcatcgagattggagtgacaaggagggaagtccacatatactatcttgaaaaggccaataaaattaaatctgagaagacacacatccacattttctcattcactggggaagaaatggccacaaaggccgactacactctcgatgaggaaagcagggctaggatcaagaccagactattcaccataagacaagaaatggctagcagaggcctctgggattcctttcgtcagtccgaaagaggcgaagaaacaattgaagaaagatttgaaatcacagggacaatgcgcaggctcgccgaccaaagtctcccgccgaacttctcctgccttgagaattttagagcctatgtggatggattcgaacccaacggctacattgagggcaagctttctcaaatgtccaaagaagtaaatgctaaaattgagccttttctgaaaacaacaccaagaccaattaaacttccggatgggcctccttgctctcagcggtccaaattcctgctgatggatgctttaaaattaagcattgaggacccaagtcacgaaggagagggaataccactatatgatgcgatcaagtgtatgagaacattctttggatggaaagaaccctatgttgttaaaccacacgataagggaataaatccaaattatctgctgtcatggaagcaattactggcagaactgcaggacattgagaatgaggagaagattccaagaaccaaaaacatgaagaaaacgagtcagctaaagtgggcacttggtgagaacatggcaccagagaaggtagactttgacgactgtagagatataagcgatttgaagcaatatgatagtgatgaacctgaattaaggtcactttcaagctggatccagaatgagttcaacaaggcatgcgagctgaccgattcaatctggatagagctcgatgagattggagaagatgtggctccaattgaacacattgcaagcatgagaaggaattacttcacagcagaggtgtctcag
tgcagagccacagaatatataatgaagggggtatacattaatactgccttgcttaatgcatcctgtgcagcaatggacgatttccaactaattcccatgataagcaaatgtagaactaaagagggaaggcgaaagaccaatttatatggtttcatcataaaaggaagatctcacttaaggaatgacaccgacgtggtaaactttgtgagcatggagttttctctcactgacccaagacttgagccacacaaatgggagaagtactgtgttcttgagataggagatatgctactaagaagtgccataggccaggtgtcaaggcccatgttcttgtatgtgaggacaaatggaacatcaaagattaaaatgaaatggggaatggagatgaggcgttgcctccttcagtcactccaacaaatcgagagtatgattgaagccgagtcctctgtcaaggagaaagacatgaccaaagagtttttcgagaataaatcagaaacatggcccattggagagtcccccaaaggagtggaagaaggttccattgggaaggtctgcaggactttattagccaagtcggtattcaatagcctgtatgcatctccacaattagaaggattttcagctgaatcaagaaaactgcttcttgtcgttcaggctcttagggacaatcttgaacctgggacctttgatcttggggggctatatgaagcaattgaggagtgcctgattaatgatccctgggttttgcttaatgcgtcttggttcaactccttcctaacacatgcattaagatagttgtggcaatgctactatttgctatccatactgtccaaaaaagtaccttgtttctact,SEQ ID NO.10。
M基因的核苷酸序列如SEQ ID NO.11所示。
agcaaaagcaggtagatattgaaaaatgagtcttctaaccgaggtcgaaacgtacgttctctctatcgtcccgtcaggccccctcaaagccgagatcgcacagagacttgaagatgtctttgctgggaagaacaccgatcttgaggctctcatggagtggctaaagacaagaccaatcctgtcacctctgactaaggggattttgggatttgtattcacgctcaccgtgcccagtgagcgaggactgcagcgtagacgctttgtccaaaatgccctcaatgggaatggggatccaaataacatggacagagcagttaaactgtatagaaagcttaagagggagataacattccatggggccaaagaaatagcgctcagttattctgctggtgcacttgccagttgtatgggcctcatatacaacaggatgggggctgtgaccactgaagtggcctttggcctggtatgtgcaacctgtgaacagattgctgactcccagcataggtctcataggcaaatggtgataacaaccaatccactaataagacatgagaacagaatggttctggccagcactacagctaaggctatggagcaaatggctggatcgagtgagcaagcagcagaggccatggaggttgctagtcaggctaggcaaatggtgcaggcaatgagagccattgggactcatcctagctccagtgctggtctaaaaagtgatcttcttgaaaatttgcaggcctatcagaaacgaatgggggtgcagatgcaacgattcaagtgaccctcttgttgttgccgcgagtatcattgggatcttgcacttgatattgtggattcttgatcgtctttttttcaaatgcaattatcgcttctttaaacacggtctgaaaagaggggcttctacggaaggagtaccagagtctatgagggaagaatatcgaaaggaacagcagagtgctgtggatactgacgatagtcattttgtcagcatagagctggagtaaaaaactaccttgtttctact,SEQ ID NO.11。
NP基因的核苷酸序列如SEQ ID NO.12所示。
Agcaaaagcagggtagataatcactcactgagtgacatcaaaatcatggcgtcccaaggcaccaaacggtcttatgaacagatggaaactgatggggaacgccagaatgcaactgaaatcagagcatccgtcgggaagatgattgatggaattggacgattctacatccaaatgtgcaccgaacttaaactcagtgattatgaggggcggctgatccagaacagcttaacaatagagagaatggtgctctctgcttttgacgagaggaggaataaatatctggaagaacatcccagcgcggggaaggatcctaagaaaactggaggacccatatacaagagagtagatggaaagtggatgagggaactcgtcctttatgacaaagaagaaataaggcgaatctggcgccaagctaataatggtgatgatgcaacagctggtctgactcacatgatgatctggcattccaatttgaatgatacaacataccagaggacaagagctcttgttcgcaccggaatggatcccaggatgtgctctttgatgcagggttcgactctccctaggaggtctggagccgcagccgctgcagtcaaaggagttgggacaatggtgatggagttgatcaggatgatcaaacgtgggatcaatgatcggaacttctggagaggtgagaatgggcggaaaacaaggattgcttatgagagaatgtgcaacattctcaaaggaaaatttcaaacagctgcacaaagagcaatgatggatcaagtgagagaaagccggaacccaggaaatgctgagatcgaagatctcatctttctggcacggtctgcactcatattgagaggctcagttgctcacaaatcttgtctgcctgcctgtgtgtatggacctgccgtagccagtgggtacgaattcgaaaaagagggatactctttagtagggatagaccctttcaaactgcttcaaaacagccaagtatacagcctaatcagaccgaacgagaatccagcacacaagagtcagctggtgtggatggcatgcaattctgctgcatttgaagatctaagagtatcaagcttcatcagagggaccaaagtaatcccaagggggaaactttccactagaggagtacaaattgcttcaaatgaaaacatggatactatggaatcaagtactcttgaactgagaagcaggtactgggccataaggaccagaagtggaggaaacactaatcaacagagggcctctgcaggtcaaatcagtgtacaacctacgttttctgtgcaaagaaacctcccatttgacaaaccaaccatcatggcagcattcactgggaatgcagagggaagaacatcagacatgagggcagaaatcataaggatgatggaaggtgcaaaaccagaagaagtgtccttccaggggcggggagtcttcgagctctcggactaaaaggcaacgaaccccatcgtgccctcttttgacatgagtaatgaaggatcttatttcttcggagacaatgcagaggagtacgacaattaaggaaaaattacccttgtttctact,SEQ ID NO.12。
所取得的有益效果:当新的重组病毒感染细胞后,本发明所构建的NS基因全长在细胞质内表达,在2A作用下血管紧张素Ⅱ和转铁蛋白被切割下来,同时转铁蛋白完成自组装形成纳米颗粒,血管紧张素Ⅱ在该纳米颗粒的表面广泛分布,在完成皮内注射后,通过内源性抗原提呈,刺激机体产生抗AngⅡ的抗体,从而拮抗高血压患者体内高水平的AngⅡ,达到降低血压的目的。
本发明的8质粒流感病毒反向遗传学拯救系统,其中的5个质粒携带的病毒基因片段来源于甲型流感病毒冷适应减毒株,具体包括:PA、PB1、PB2、M和NP基因,它们具备低温减毒的特性,保证了所制备的疫苗的减毒特征和安全性。
本发明的8质粒流感病毒反向遗传学拯救系统,其中的2个质粒携带的病毒基因片段分别是HA和NA,它们则来源于本年度世界卫生组织在北半球推荐使用的流感病毒疫苗株(流感疫苗候选株),保证了所制备的疫苗与世界卫生组织推荐疫苗株的匹配程度,使得接种者最大受益。实现“一针防两病”的目的:预防流感病毒感染和治疗高血压。
本发明所使用质粒携带的NS基因片段是经过改造的,使得该活病毒对机体免疫系统产生的干扰素敏感,在机体细胞内复制受到限制,从而进一步保障了所制备的疫苗的安全性。
进一步的,所述转铁蛋白为人转铁蛋白或幽门螺旋杆菌转铁蛋白。
进一步的,所述改造后流感病毒NS基因片段的核苷酸序列如SEQ ID NO.1所示。
进一步的,所述双向表达质粒为pHW2000或pAD3000。
进一步的,所述甲型流感病毒冷适应减毒株为A/AnnArbor/6/60、A/Yunnan/1/2005Vca(H3N2)、A/Leningrad/134/17/57 (H2N2)。
进一步的,所述哺乳动物细胞为293T细胞、COS7细胞、MDCK细胞、Vero细胞。
进一步的,还包括纯化步骤,所述纯化包括超滤浓缩、蔗糖密度梯度离心、疏水层析和阴离子层析。
上述制备方法制备的疫苗,通过皮内注射方式进行免疫。
经由上述的技术方案可知,与现有技术相比,本发明取得的有益效果为:
(1)本发明提供的重组流感病毒载体治疗性高血压疫苗,其表达的带有AngⅡ的转铁蛋白自组装成纳米颗粒,需要在胞内完成,然后通过抗原提呈细胞进一步发挥免疫应答作用,由于机体皮内的天然免疫细胞丰富,如朗格汉斯细胞、树突细胞、NK细胞等,使得抗原提呈高效,并能有效节约抗原用量,进一步保障了疫苗的安全性。本发明制备的疫苗具备更广泛的适用性,并可激活有效的粘膜免疫和细胞免疫,有效性、安全性更加确切。
(2)本发明制备的重组流感病毒载体治疗性高血压疫苗经皮内免疫后能够取得较好的免疫原性,提高免疫保护效果,免疫持久性强。结合无针注射器的使用,能够有效增加患者接种的依从性。
(3)本发明提供的病毒拯救方法具有时效性,能根据每年流感病毒的流行特点,为高血压患者针对性的制备有效的流感疫苗,制备快速,免疫原性、免疫保护效果显著,并且具有很好的安全性。本发明所采用的反向遗传操作技术,应用于流感病毒的拯救先进而成熟,具有方便简捷、定位可控等优点。
附图说明
为了更清楚地说明本发明实施例或现有技术中的技术方案,下面将对实施例或现有技术描述中所需要使用的附图作简单地介绍,显而易见地,下面描述中的附图仅仅是本发明的实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据提供的附图获得其他的附图。
图1为本发明血管紧张素II与高血压之间的关系模式图;
图2为本发明实施例2中天然NS1蛋白结构模式图;
图3为本发明实施例2中人转铁蛋白和NS1共表达的模式图;
图4为本发明实施例2中人转铁蛋白从NS1上通过2A自酶切后形成两个独立的蛋白模式图,其中,左侧为NS1二聚体,右侧为人转铁蛋白形成的二聚体;
图5为本发明实施例2中被截短的NS1蛋白;
图6为本发明实施例2中被2A自酶切下来的人转铁蛋白具备自组装能力;
图7为本发明实施例3中SBP降压效果监测结果;
图8为本发明实施例3中DBP降压效果监测结果。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明所需药剂为常规实验药剂,采购自市售渠道;未提及的实验方法为常规实验方法,在此不再一一赘述。
实施例1
重组流感病毒载体治疗性高血压疫苗的制备
1)以流感病毒A/New Caledonia/20/99(H1N1)的NS基因为模板,对NS基因进行目的性改造:
即将原NS1基因的237个氨基酸序列截短为前113个氨基酸,在其后面依次插入2A肽氨基酸序列,增加9个重复的血管紧张素Ⅱ(AngⅡ)氨基酸序列,增加人转铁蛋白(HF)氨基酸序列,然后连接上NS2氨基酸序列。通过分子生物酶切(如BspQI酶),在连接酶的作用下,按照酶说明书进行具体操作,使得改造后流感病毒NS基因片段与双向表达质粒(如pHW2000或pAD3000)进行连接,构建重组双向表达质粒,命名为:re-NS。
改造后流感病毒NS基因片段的核苷酸序列如SEQ ID NO.1所示。
ATGGACAGCCACACCGTGAGCAGCTTCCAGGTGGACTGCTTCCTGTGGCACGTGAGGAAGCAGGTGGCCGACCAGGACCTGGGCGACGCCCCCTTCCTGGACAGGCTGAGGAGGGACCAGAAGAGCCTGAAGGGCAGGGGCAGCACCCTGGGCCTGAACATCGAGACCGCCACCTGCGTGGGCAAGCAGATCGTGGAGAGGATCCTGAAGGAGGAGAGCGACGAGGCCTTCAAGATGACCATGGCCAGCGCCCTGGCCAGCAGGTACCTGACCGACATGACCATCGAGGAGATGAGCAGGGACTGGTTCATGCTGATGCCCAAGCAGAAGGTGGCCGGCGCCACCAACTTCAGCCTGCTGAAGCAGGCCGGCGACGTGGAGGAGAACCCCGGCCCCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGACAGGGTGTACATCCACCCCTTCGTGGACTGCAGCACCCTGATCCTGAACATGGCCGACTGCCTGAGCTTCGTGAGCAGCGGCGGCACCGTGGCCAAGCCCGAGGGCACCTGCTGCAGCGGCCTGAAGACCGTGCTGAAGGCCGACAGCCAGTGCCTGTGCGAGGCCTTCAAGAGCAGCGCCAGCCTGGGCGTGACCCTGAACATCACCAAGGCCAGCACCCTGCCCGCCGCCTGCAAGCTGCACGCCCCCATGGACAGCCACACCGTGAGCAGGTTCGGCGACATCCTGATGAGGATGAGCAAGATGGGCCTGGGCAGCAGCAGCGGCGACCTGAACGGCATGATCACCCAGTTCGAGAGCCTGAAGCTGTACAGGGACAGCCTGGGCGAGGCCGTGATGAGGCTGGGCGACCTGCACAGCCTGGGCCACAGGAACGGCAAGTGGAGGGAGGGCCTGGGCGGCAAGTTCGAGGAGATCAGGTGGCTGATCGAGGAGGTGAGGCACAAGCTGAAGACCACCGAGAACAGCTTCGAGGGCATCACCTTCATGGGCGCCCTGGGCCTGCTGTTCGAG,SEQ ID NO.1。
改造后流感病毒NS基因片段编码的氨基酸序列如SEQ ID NO.2所示。
MDSHTVSSFQVDCFLWHVRKQVADQDLGDAPFLDRLRRDQKSLKGRGSTLGLNIETATCVGKQIVERILKEESDEAFKMTMASALASRYLTDMTIEEMSRDWFMLMPKQKVAGATNFSLLKQAGDVEENPGPDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFVDCSTLILNMADCLSFVSSGGTVAKPEGTCCSGLKTVLKADSQCLCEAFKSSASLGVTLNITKASTLPAACKLHAPMDSHTVSRFGDILMRMSKMGLGSSSGDLNGMITQFESLKLYRDSLGEAVMRLGDLHSLGHRNGKWREGLGGKFEEIRWLIEEVRHKLKTTENSFEGITFMGALGLLFE,SEQ ID NO.2。
其中,截短后的NS1基因编码的前113个氨基酸序列如SEQ ID NO.3所示。
MDSHTVSSFQVDCFLWHVRKQVADQDLGDAPFLDRLRRDQKSLKGRGSTLGLNIETATCVGKQIVERILKEESDEAFKMTMASALASRYLTDMTIEEMSRDWFMLMPKQKVAG,SEQ ID NO.3。
2A肽(P2A)的氨基酸序列如SEQ ID NO.4所示。
ATNFSLLKQAGDVEENPGP,SEQ ID NO.4。
9个重复的血管紧张素Ⅱ(AngⅡ)的氨基酸序列如SEQ ID NO.5所示。
DRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPFDRVYIHPF,SEQ ID NO.5。
人转铁蛋白(HF)的氨基酸序列如SEQ ID NO.6所示。
VDCSTLILNMADCLSFVSSGGTVAKPEGTCCSGLKTVLKADSQCLCEAFKSSASLGVTLNITKASTLPAACKLHAP,SEQ ID NO.6。
NS2的氨基酸序列如SEQ ID NO.7所示。
MDSHTVSRFGDILMRMSKMGLGSSSGDLNGMITQFESLKLYRDSLGEAVMRLGDLHSLGHRNGKWREGLGGKFEEIRWLIEEVRHKLKTTENSFEGITFMGALGLLFE,SEQ ID NO.7。
2)选用甲型流感病毒冷适应减毒株A/AnnArbor/6/60(AA) (H2N2)为母本株,提供PB1、PB2、NP、PA的4个基因片段,即PB1 GenBank: AY210012.1;PB2 GenBank: AY209938.1;NP GenBank: AY210074.1;PA GenBank: AY209994.1。选用甲型流感病毒冷适应减毒株A/Leningrad/134/17/57 (H2N2)为母本株,提供M基因,即:M GenBank: M81576.1。
通过反向遗传学的方法,分别将其基因片段PB2基因、PB1基因、PA基因、M基因、NP基因与双向表达质粒进行连接,构建重组双向表达质粒,分别命名为:AA-PB2、AA-PB1、AA-PA、AA-M和AA-NP。
3)选用世界卫生组织推荐的2022年度北半球流感疫苗候选株A/New Caledonia/20/99(H1N1)的HA基因GenBank: AJ344014.1和A/Victoria/2004/2009(H1N1)的NA基因GenBank: GQ243762.1,构建主要表位基因。
通过反向遗传学的方法将HA基因和NA基因分别与双向表达质粒进行连接,构建重组双向表达质粒,命名为:re-HA和re-NA。
上述重组双向表达质粒的构建方法为:
根据上述基因和其对应的基因号,通过化学合成得到相应的核苷酸序列,将它们分别连接于构建好的载体pHW2000上,构建重组双向表达质粒。
也可以分别对流感病毒提取病毒的总RNA,从母本株用PCR的方法扩增PB1、PB2、NS、M、NP、PA、HA、NA基因片段,测序后分别连接于构建好的载体pHW2000上,构建重组双向表达质粒。
载体pHW2000的构建参照Hoffmann E,Neumann G,Kawaoka Y,Hobom G,WebsterRG.A DNA transfectionsystem for generation of influenza A virus from eightplasmids.Proc Natl Acad SciU S A.2000May 23;97(11)6108-13。
4)如上所述8个重组双向表达质粒归纳为:含有PB2编码基因的重组双向表达质粒(AA-PB2)、含有PB1编码基因的重组双向表达质粒(AA-PB1)、含有PA编码基因的重组双向表达质粒(AA-PA)、含有M编码基因的重组双向表达质粒(AA-M)、含有NS编码基因的重组双向表达质粒(re-NS)、含有NP编码基因的重组双向表达质粒(AA-NP)、含有HA编码基因的重组双向表达质粒(re-HA)和含有NA编码基因的重组双向表达质粒(re-NA)。
利用反向遗传技术拯救流感病毒疫苗株。培养细胞系293T细胞,通过脂质体或电穿孔转染受体细胞系。将含有流感病毒PB1、PB2、PA、NP、M、NS、HA、NA基因片段的8个重组双向表达质粒共转染上述细胞系。
流感病毒反向遗传操作技术具体如下:
①提取质粒:使用无内毒素小量中提试剂盒提取即可,提取质粒后对质粒质量进行控制:
浓度范围600~3000ng/μL;
A260:A280范围1.8~1.99;
常规DNA电泳图显示单一条带,大小正确;
②稀释质粒:共8个质粒,每个质粒终浓度为100ng/μL,稀释液使用无核酸酶的水即可;
③转染:以转染试剂盒为例,对8个质粒,每个质粒取2μL,共计16μL,与Buffer EC84μL,共计100μL,在EP管中混匀;加入Enhanser 12μL,再次混匀,室温静止5min;加入转染剂15μL,混匀,室温静止15min;加入500μL的细胞生长液(基础培养基DMEM,加入体积比为10%的胎牛血清),混匀后,滴加到6孔板的细胞面上,轻轻摇匀后,37℃,静止培养12~18hour;
④转染前的细胞准备:在转染前的24小时准备细胞,使用293T细胞,胞龄控制在24hour,转染操作前,先对细胞换液处理,弃全部细胞培养液,加入新鲜培养液,6孔板中,每孔加入2.5mL;
⑤转染后的换液:在转染后的12~18hour后,对细胞进行换液,弃全部培养液,加入新鲜培养液,6孔板中,每孔加入3mL;
⑥换液后的收获:在37℃条件下,换液后继续静止培养至48~72 hour后收毒。收毒方法收获将整个细胞培养板冻于-80℃冰箱内,冻融一次后接种鸡胚;
⑦接种11日龄的鸡胚,收集上一步获得的全部液体接种鸡胚,每个鸡胚接种0.9mL,收获液全部予以接种鸡胚。在温度37℃和湿度60%条件下培养鸡胚72小时后,在4℃冷胚过夜。收集鸡胚尿囊液,建立原代种子库(即本发明所述重组流感病毒载体治疗性高血压疫苗的原始病毒种子),完成流感病毒的反向遗传学拯救。
通过超滤浓缩、蔗糖密度梯度离心、疏水层析和阴离子层析的方法纯化后获得的治疗性高血压疫苗也属于本发明的保护范围。
5)工作种子的系统性检测
检测指标包括:采用红细胞凝集试验测定病毒的滴度(>1:160)、细胞病变法测定病毒的TCID50(>100)、鸡胚感染力测定EID50(>100)、免疫扩散法测定血凝素型别和血凝素含量(血凝素型别鉴别试验符合药典要求)、采用电镜观察病毒颗粒(能够观察到完整病毒颗粒)、SDS-PAGE测定病毒的主要蛋白抗原成分(蛋白电泳条带数目和大小正确)、间接免疫荧光测定病毒的抗原表达特异性。
重组流感病毒载体治疗性高血压疫苗株种子库毒株或传代至15代的病毒株采用RT-PCR测定血管紧张素和人转铁蛋白的稳定性(基因测序证实序列一致)。
将该重组流感病毒载体治疗性高血压疫苗在鸡胚上培养,增殖培养后收集病毒液,对病毒液超滤浓缩、柱层析纯化,制备治疗性疫苗半成品。进一步制备成皮内注射活疫苗成品剂型。该重组流感病毒载体治疗性高血压疫苗在SRH大鼠体内进行安全性、有效性、稳定性的研究。
建立哺乳动物细胞培养用于该病毒疫苗株的策略,采用微载体技术、片状载体生产流感病毒,用MDCK培养基,常规的培养基包括MEM、DMEM等。培养基的pH值为6.8~7.3,PO2为35%~60%,m.o.i(multiplicity of infection)为0.002~0.5。接种病毒后加入胰蛋白酶帮助切割流感病毒HA0蛋白,才能使流感病毒吸附于细胞,进而进入细胞进行复制。
实施例2
改造后的NS1蛋白表达、人转铁蛋白自组装和AngⅡ工作原理
如图2-图6所示。
图2为天然NS1蛋白结构模式图。拮抗宿主干扰素产生的原理:甲型流感病毒感染人体后会诱发宿主的天然免疫应答,通过Toll样受体和RIG样受体等模式识别受体介导的信号通路,诱导I型干扰素以及其它的细胞因子产生,发挥抗病毒作用。其中NS1可结合病毒的双链RNA,靶向RIG和E3泛素连接酶TRIM25等方式抑制宿主发挥抗病毒作用。
图3为人转铁蛋白和NS1共表达的模式图。人转铁蛋白的一个单体,其在细胞内表达后紧靠着NS1蛋白。表达之后,在2A自酶切发生之前,两者均具有较好的空间结构
图4为人转铁蛋白从NS1上通过2A自酶切后形成两个独立的蛋白模式图。左侧为NS1二聚体,人转铁蛋白不再黏附其上。右侧为人转铁蛋白形成的二聚体,呈独立状态。AngⅡ表达在其表面,即每一个人转铁蛋白单体上具有9个AngⅡ,二聚体人转铁蛋白表面具有18个AngⅡ。
图5为被截短的NS1蛋白,其前113个氨基酸序列仍然保持六个α螺旋的空间结构对病毒RNA的结合能力,保证了病毒的复制活性。但是其尾部被截短和取代后,不完整,不能刺激Toll样受体和RIG样受体等模式识别受体介导的信号通路,保障了重组流感病毒载体在细胞内的有限的复制能力。
图6为被2A自酶切下来的人转铁蛋白具备自组装能力,无需特殊处理和媒介作用,24个人转铁蛋白能够自组装成一个完整的纳米颗粒模式图。该纳米颗粒为实心颗粒,AngⅡ表达在其表面。即24个人转铁蛋白形成的纳米颗粒表面有216个AngⅡ覆盖在上面,保障了其重复的抗原性。
实施例3
重组流感病毒载体治疗性高血压疫苗对模式动物SHR的治疗效果
(1)实验动物:
购买自北京维通利华实验动物技术有限公司。12周龄,平均体重250g,雄性SHRs大鼠。它是自发性高血压大鼠,在发病后其血压高出正常大鼠血压水平。
(2)动物免疫:
初次免疫:大鼠进入实验室适应一周后,采用两后股四头肌处免疫的方式对大鼠进行免疫。免疫前禁水、禁食,第0周进行初次免疫,免疫剂量为250μg/只。
加强免疫:在初次免疫后第21天,再加强免疫1次,免疫剂量和方法同前。
空白对照组在相同条件下注射生理盐水。
(3)血压的测定:
按照SoftronTM智能无创血压计BP-98A(北京软隆科技有限责任公司)操作手册,采用无创尾压测量法来测量尾部动脉血压。
第0、2、4、8、10、12周测量血压并记录。结果如图7、图8所示。
图7结果表明,在使用本发明制备的重组流感病毒载体治疗性高血压疫苗治疗后,自发性高血压大鼠的收缩压(SBP)降压效果监测显示,经过治疗后的第2周开始出现血压下降趋势,在治疗后的第6周降压到最佳效果,并能够维持在155mmHg上下范围波动。图8结果表明,在使用本发明制备的重组流感病毒载体治疗性高血压疫苗治疗后,自发性高血压大鼠的舒张压(DBP)降压效果监测显示,在经过治疗后的第6周出现血压的显著降低,在第8周开始出现一定程度的升高,但仍然低于对照组的DBP值。
(4)抗体滴度的测定:
1)在治疗后的第12周采集模式动物的周尾静脉采血,采血液后,将血液于37℃水浴中放置或于4℃冰箱中放置过夜,离心,收集血清,于56℃水浴中放置半小时灭活血清,并进行分装,保存于-20℃备用。
2)用AngⅡ(conjugated to bovine serum albumin)包被96孔酶标板,使用浓度为100μg/mL,(每孔100μL),4℃包被过夜。
3)将包被板从2~8℃取出后,洗板4次,每次洗液体积为300μl/孔,洗完后若孔内残留洗液,在吸水纸上拍干,加入预先配制的封闭液,300μl/孔,盖封板膜,37±1℃孵育90分钟。
4)参考品处理:根据参考品标示抗原含量,以150mmol/L氯化钠溶液稀释至80μg/ml,再加等量处理液稀释为40μg/ml(已加处理液的上清为2倍稀释液),在EP管中用样品稀释液10倍稀释至4000ng/ml。
5)加样:取出封闭后的酶标板,弃去封闭液,加入洗涤液300μl/孔,轻轻震荡约30s,弃掉洗液,每次洗涤均尽量弃尽孔内残留洗液,并在吸水纸上拍干,重复洗涤4次。将稀释好的各个浓度的工作参考品、质控组及供试品解吸附稀释液、供试品未解吸附稀释液依次加入到板孔中,100μl/孔,平行2个复孔;加入100μl/孔样品稀释液作为阴性对照,平行2孔。盖上封板膜,37±1℃孵育60分钟。
6)加酶标记二抗:弃去孔内液体,用洗涤液洗板4次,每次洗涤液体积为300μl/孔,每次洗涤均尽量弃尽孔内残留洗液,在吸水纸上拍干;加入稀释好的酶标记二抗,100μl/孔,盖封板膜,37±1℃,孵育60分钟。
7)显色:弃去96孔板内的酶标记二抗,洗板4次,每次洗涤液体积为300μl/孔,每次洗涤均尽量弃尽孔内残留洗液,在吸水纸上拍干;加TMB显色液(提前从2~8℃取出,平衡至室温),100μl/孔,37℃避光显色15分钟。
8)终止:显色到时后立即加终止液100μl/孔,轻微震荡混匀。
9)检测:加终止液后,立即将酶标板放入酶标仪,在450nm/630nm波长下测吸光度值。
在治疗的第12周,测定血清结果显示:治疗组的平均吸光度值为0.6557±0.0053,空白对照组的平均吸光度值为0.0179±0.0046。结果显示两组之间具有显著差异。
本发明制备的重组流感病毒载体治疗性高血压疫苗,目前没有进入临床试验,不能确定准确的注射次数和剂量。但是根据动物和人的年龄和体重相对比值,可以6个月注射一次,注射剂量<1000PFU/剂。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (8)
1.一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,包括如下步骤:
(1)对流感病毒NS基因进行目的性改造:
将原NS1基因的237个氨基酸序列截短为前113个氨基酸,在其后面依次插入2A肽氨基酸序列,增加9个重复的血管紧张素Ⅱ氨基酸序列,增加转铁蛋白氨基酸序列,然后连接上NS2氨基酸序列,得改造后流感病毒NS基因片段;
(2)将所述改造后流感病毒NS基因片段与双向表达质粒连接,构建重组双向表达质粒,命名为re-NS;
(3)将甲型流感病毒冷适应减毒株作为母本株,分别将其基因片段PB2基因、PB1基因、PA基因、M基因、NP基因与双向表达质粒连接,构建重组双向表达质粒,分别命名为:AA-PB2、AA-PB1、AA-PA、AA-M、AA-NP;
(4)将世界卫生组织在北半球推荐使用的甲型流感病毒毒株的HA基因和NA基因分别与双向表达质粒连接,构建重组双向表达质粒,分别命名为re-HA、re-NA;
(5)将构建的8个重组双向表达质粒共转染哺乳动物细胞,培养收毒即可。
2.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,所述转铁蛋白为人转铁蛋白或幽门螺旋杆菌转铁蛋白。
3.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,所述改造后流感病毒NS基因片段的核苷酸序列如SEQ ID NO.1所示。
4.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,所述双向表达质粒为pHW2000或pAD3000。
5.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,所述甲型流感病毒冷适应减毒株为A/AnnArbor/6/60、A/Yunnan/1/2005Vca(H3N2)、A/Leningrad/134/17/57 (H2N2)。
6.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,所述哺乳动物细胞为293T细胞、COS7细胞、MDCK细胞、Vero细胞。
7.如权利要求1所述的一种重组流感病毒载体治疗性高血压疫苗的制备方法,其特征在于,还包括纯化步骤,所述纯化包括超滤浓缩、蔗糖密度梯度离心、疏水层析和阴离子层析。
8.权利要求1-7任一所述制备方法制备的疫苗,其特征在于,通过皮内注射方式进行免疫。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311001106.9A CN116751818B (zh) | 2023-08-10 | 2023-08-10 | 一种重组流感病毒载体治疗性高血压疫苗的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311001106.9A CN116751818B (zh) | 2023-08-10 | 2023-08-10 | 一种重组流感病毒载体治疗性高血压疫苗的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN116751818A true CN116751818A (zh) | 2023-09-15 |
CN116751818B CN116751818B (zh) | 2024-01-26 |
Family
ID=87951637
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311001106.9A Active CN116751818B (zh) | 2023-08-10 | 2023-08-10 | 一种重组流感病毒载体治疗性高血压疫苗的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN116751818B (zh) |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101243189A (zh) * | 2005-06-21 | 2008-08-13 | 米迪缪尼疫苗股份有限公司 | 用于在犬细胞内表达反义病毒rna的方法和组合物 |
CN101532030A (zh) * | 2009-04-21 | 2009-09-16 | 中国科学院广州生物医药与健康研究院 | 一种na片段携带外源基因的重组流感病毒载体及其制备方法和应用 |
CN103740654A (zh) * | 2014-01-27 | 2014-04-23 | 中国医学科学院医学生物学研究所 | 一种乙型流感病毒Vero细胞冷适应株及其应用 |
CN103898066A (zh) * | 2014-01-27 | 2014-07-02 | 中国医学科学院医学生物学研究所 | 一种甲型流感病毒Vero细胞冷适应株及其应用 |
CN113069540A (zh) * | 2021-03-15 | 2021-07-06 | 广州恩宝生物医药科技有限公司 | 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法 |
CN113186173A (zh) * | 2021-04-15 | 2021-07-30 | 上海生物制品研究所有限责任公司 | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 |
US20210299249A1 (en) * | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
CN113730566A (zh) * | 2021-11-08 | 2021-12-03 | 天津中逸安健生物科技有限公司 | 一种流感新冠联合疫苗及其制备方法 |
WO2022109068A1 (en) * | 2020-11-17 | 2022-05-27 | Vivaldi Biosciences Inc. | Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain |
-
2023
- 2023-08-10 CN CN202311001106.9A patent/CN116751818B/zh active Active
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101243189A (zh) * | 2005-06-21 | 2008-08-13 | 米迪缪尼疫苗股份有限公司 | 用于在犬细胞内表达反义病毒rna的方法和组合物 |
CN101532030A (zh) * | 2009-04-21 | 2009-09-16 | 中国科学院广州生物医药与健康研究院 | 一种na片段携带外源基因的重组流感病毒载体及其制备方法和应用 |
CN103740654A (zh) * | 2014-01-27 | 2014-04-23 | 中国医学科学院医学生物学研究所 | 一种乙型流感病毒Vero细胞冷适应株及其应用 |
CN103898066A (zh) * | 2014-01-27 | 2014-07-02 | 中国医学科学院医学生物学研究所 | 一种甲型流感病毒Vero细胞冷适应株及其应用 |
US20210299249A1 (en) * | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
WO2022109068A1 (en) * | 2020-11-17 | 2022-05-27 | Vivaldi Biosciences Inc. | Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain |
CN113069540A (zh) * | 2021-03-15 | 2021-07-06 | 广州恩宝生物医药科技有限公司 | 一种基于流感病毒载体的新型冠状病毒疫苗及其制备方法 |
CN113186173A (zh) * | 2021-04-15 | 2021-07-30 | 上海生物制品研究所有限责任公司 | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 |
CN113730566A (zh) * | 2021-11-08 | 2021-12-03 | 天津中逸安健生物科技有限公司 | 一种流感新冠联合疫苗及其制备方法 |
Non-Patent Citations (2)
Title |
---|
戴军等: "流感病毒NS1蛋白抗高血压作用的研究", 《科技成果》, pages 1 * |
王东红等: "流感病毒载体疫苗的构建策略", 《病毒学报》, vol. 38, no. 06, pages 1478 - 1487 * |
Also Published As
Publication number | Publication date |
---|---|
CN116751818B (zh) | 2024-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI495724B (zh) | 流行性感冒病毒的救援技術(二) | |
JP6375329B2 (ja) | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス | |
ES2523587T3 (es) | Virus influenza B que tienen alteraciones en el polipéptido hemaglutinina | |
US11305007B2 (en) | Composite multi-epitope expression cassette, a recombinant virus composed thereof and application thereof | |
CN113186173B (zh) | 一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗 | |
KR20070086344A (ko) | 탠덤 전사 유닛을 갖는 재조합 인플루엔자 벡터 | |
CN106995802A (zh) | 流感病毒突变体及其用途 | |
KR20120132506A (ko) | 인플루엔자 바이러스 질환의 예방 및 치료에 사용되는 백신 | |
CN104395336A (zh) | 以计算方式优化的h5n1和h1n1流感病毒的广泛反应性抗原 | |
CN101636177A (zh) | 用于禽流感的基于重组改良型痘苗病毒安卡拉(mva)的疫苗 | |
US20100099745A1 (en) | Enhancing disease resistance against rna viral infections with intracytoplasmic pathogen sensors | |
KR102180774B1 (ko) | H5N8형 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4A에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물 | |
CN105518129B (zh) | 减毒流感疫苗和其用途 | |
CN1487999A (zh) | 编码血管生成基因的副粘病毒载体及其应用 | |
US20230414745A1 (en) | Influenza virus encoding a truncated ns1 protein and a sars-cov receptor binding domain | |
US9060972B2 (en) | Recombinant hemagglutinin protein of influenza virus and vaccine containing the same | |
CN113398259A (zh) | 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用 | |
CN116751818B (zh) | 一种重组流感病毒载体治疗性高血压疫苗的制备方法 | |
CN116327910B (zh) | 一种新冠病毒、流感病毒和/或rsv的联合疫苗、其制备方法与应用 | |
CN102272302A (zh) | 增强重组蛋白表达的方法 | |
RU2701953C1 (ru) | Способ получения поливалентной вакцины от гриппа | |
CN104151402B (zh) | 病毒性心肌炎环肽疫苗及其制备方法 | |
CN110042084A (zh) | 一种活病毒流感疫苗的生产方法以及制剂 | |
RU2706191C1 (ru) | Поливалентная вакцина против гриппа | |
Sakaguchi et al. | Studies on the paramyxovirus accessory genes by reverse genetics in the Sendai virus–mouse system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |